Answers are grounded in this paper and cite their sources.
, Janus kinase (JAK) inhibitors are non-receptor, low- molecular-weight tyrosine kinase inhibitors that inhibit intra-cellular members of the JAK family, including JAK1, JAK2, JAK3, and TYK2. In Japan, five JAK inhibitors—tofacitinib, baricitinib, peficitinib, upadacitinib, and filgotinib—have been approved for rheumatoid arthritis (RA). Adverse events associated with JAK inhibitors include cancer, cardiovascular and thrombotic events, and serious infections. Clinical trials and real-world data have consistently shown a significantly increased risk of herpes zoster (HZ) in patients with RA receiving JAK inhibitors and have further indicated that HZ incidence differs among JAK inhibitors, with the risk potentially lowest for filgotinib [1]. We therefore examined differences in HZ incidence, risk factors for HZ, and permanent drug discontinuation rates following HZ in patients with RA treated with a JAK inhibitor. This retrospective observational study included Japanese patients with RA treated with JAK inhibitors at Jichi Medical University and affiliated hospitals between 2013 and August 2024. Demographic data were collected from electronic medical charts. For each JAK inhibitor, we examined HZ events, total observation period, time to HZ development, incidence of HZ
No takes yet. Share an insight, caveat, or question.
Sato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: